Sugi Predict

Sugi Predict / Compounds / SCHEMBL2389984

SCHEMBL2389984

SCHEMBL2389984

COc1cc(-c2ccco2)cc(OC)c1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 1/20 0.56
▸ SMN1; SMN2 Q16637 6/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ TP53 P04637 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ NFKB1 P19838 1/20 0.49
▸ NFKB2 Q00653 1/20 0.49
▸ RELA Q04206 1/20 0.49
▸ MAPT P10636 3/20 0.48
▸ TSHR P16473 3/20 0.48
▸ ADORA2A P29274 3/20 0.46
▸ SMPD3 Q9NY59 1/20 0.44
▸ ALDH1A1 P00352 7/20 0.43
▸ HPGD P15428 6/20 0.43
▸ NPC1 O15118 4/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ LMNA P02545 3/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18173535 0.89 ERN1 (0.57) ERN1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL17471104 0.86 ERN1 (0.45) ERN1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL18173532 0.84 ERN1 (0.43) ERN1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL2389780 0.84 ERN1 (0.57) ERN1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL2388588 0.84 MAPT (0.64) ERN1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL2388856 0.83 MAPT (0.53) ERN1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL18173531 0.83 ERN1 (0.43) ERN1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL2387527 0.82 ERN1 (0.56) ERN1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL2387255 0.82 ERN1 (0.73) ERN1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL12330908 0.82 ERN1 (0.56) ERN1SMN1; SMN2MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3137461-B1 METHOD OF PREPARING AN OPTICALLY ACTIVE PDE10 INHIBITOR OMEROS CORP (US) 2021-08-11 — — EP disclosed
CN-106255690-B Optically active PDE10 inhibitors 奥默罗斯公司 2020-07-17 — — CN disclosed
EP-2544679-B1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORP (US) 2019-05-15 — — EP disclosed
EP-2544679-B1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORP (US) 2019-05-15 — — EP disclosed
EP-3137462-B1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF A PDE10 INHIBITOR OMEROS CORP (US) 2019-01-30 — — EP disclosed
EP-3137462-B1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF A PDE10 INHIBITOR OMEROS CORP (US) 2019-01-30 — — EP disclosed
US-10106516-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2018-10-23 — — US disclosed
US-9920045-B2 Solid state forms of a PDE10 inhibitor OMEROS CORPORATION (US) 2018-03-20 — — US disclosed
US-9920045-B2 Solid state forms of a PDE10 inhibitor OMEROS CORPORATION (US) 2018-03-20 — — US disclosed
US-9920045-B2 Solid state forms of a PDE10 inhibitor OMEROS CORPORATION (US) 2018-03-20 — — US disclosed
US-20130196994-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2013-08-01 — — US disclosed
EP-2544679-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS Omeros Corporation (US) 2013-01-16 — — EP disclosed
US-8343970-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-01-01 — — US disclosed
US-8343970-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-01-01 — — US disclosed
US-8343970-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-01-01 — — US disclosed
WO-2011112828-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — WO disclosed
WO-2011112828-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — WO disclosed
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — US disclosed
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — US disclosed
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106516-B2 PDE10 inhibitors and related compositions and methods PDE10A, PDE9A, PDE7A ERN1 4401/4885SMN1; SMN2 527/4885MEN1 3291/4885
US-20130196994-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A ERN1 4401/4885SMN1; SMN2 527/4885MEN1 3291/4885
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A ERN1 4401/4885SMN1; SMN2 527/4885MEN1 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.